Milestone payments could take the total value of the deal to over $112 million.
Sanofi pasteur exclusively licensed Crucell’s rabies mAbs. Crucell could earn up to $112.7 million through this agreement.
Crucell will receive $14.73 million, or €10 million, following the execution of the agreement. The company is also eligible to milestone fees of up to $97.97 million, or €66.5 million.
Crucell says it has developed a combination of two compounds that have shown preclinical results comparable to current immunoglobulin products. These biologics will be combined with a vaccine as a post-exposure prophylaxis, according to the firms.
Crucell will continue to develop the candidates and will manufacture the final product.